Anthony Pham, MD
Hematology & Oncology · Tigard, ORNPI 1790913994
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,463 of the $1,915 with a category attached, or 76.4%. Beigene USA, Inc. accounts for 78.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,527 and has fallen 97.2% since, to $42 in 2025.
Across 10 payments — averaging $191.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$2K
- Sirtex Medical Inc$189
- Biocompatibles, Inc.$114
- Astellas Pharma US Inc$42
- Otsuka America Pharmaceutical, Inc.$20
- AVEO Pharmaceuticals, Inc.$15
- plus $23 from 2 others
Across 132 payments — averaging $5764.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$486K
- Eli Lilly$221K
- Amgen$20K
- Chugai Pharmaceutical Co., Ltd.$11K
- AVEO Pharmaceuticals, Inc.$11K
- Mirati Therapeutics, Inc.$9K
- plus $3K from 1 others
What the payments were for
- Consulting fees$1,46376%
- Food & beverage$41422%
- Education$382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 2 | $1,512 |
| Sirtex Medical Inc | 1 | $189 |
| Biocompatibles, Inc. | 1 | $114 |
| Astellas Pharma US Inc | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$1,463
- SIR-Spheres Microspheres$189
- THERASPHERE-BIO$114
How this compares
$1,915 in reported general payments places this provider in the 65th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 34 | $479,954 |
| XtandiEnzalutamide | 30 | $430,696 |
| JakafiRuxolitinib Phosphate | 23 | $384,943 |
| IbrancePalbociclib | 20 | $310,525 |
| ErleadaApalutamide | 19 | $278,135 |
| RevlimidLenalidomide | 15 | $262,138 |
| ImbruvicaIbrutinib | 11 | $120,381 |
| ZytigaAbiraterone Acetate | 13 | $106,670 |
| Abiraterone Acetate | 226 | $86,738 |
| EliquisApixaban | 44 | $37,130 |
| Oxycodone Hcl | 57 | $1,330 |
| Bicalutamide | 13 | $1,223 |
| Prochlorperazine Maleate | 56 | $1,187 |
| Hydroxyurea | 44 | $1,178 |
| Megestrol Acetate | 30 | $1,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $42 | $430,69630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Tigard
- Brian DrukerPortland$1.9M
- Bo WangCorvallis$251K
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Christopher YasenchakEugene$102K
- Elie TraerPortland$72K
- Luke FletcherEugene$44K
- Jeffrey MenashePortland$38K
- Michael HeinrichPortland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.